Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

361
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
361
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

684
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
684
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

251
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
251
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

30
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
30
Neural Regulation01:37

Neural Regulation

39.7K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.7K
Cancer Prevention02:59

Cancer Prevention

6.3K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Alzheimer´s disease blood biomarkers are associated with a higher risk for postoperative long-term cognitive decline: Insights from the FINDERI study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

A comprehensive assessment of lifecourse and mortality of Parkinson's disease in the German National Cohort.

NPJ Parkinson's disease·2026
Same author

Teleguided Point-of-Care Ultrasound for Fluid Assessment in Geriatric Inpatients Performed by Nurses and Medical Students: Prospective Observational Feasibility Study.

JMIR formative research·2026
Same author

Genetic associations between post-traumatic stress disorder and REM-sleep behavior disorder.

NPJ Parkinson's disease·2026
Same author

A multimodal biomarker strategy to enhance diagnostic precision in neurodegenerative parkinsonism.

Nature medicine·2026
Same author

Multi-locus genetic dosage shapes cognitive disease progression in Parkinson's patients: 15-year meta-analysis of 24 cohorts.

NPJ Parkinson's disease·2026

Related Experiment Video

Updated: Sep 1, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.0K

Toward preventing Parkinson's disease.

Brit Mollenhauer1, Christine A F von Arnim2

  • 1Department of Neurology, University Medical Center Göttingen and Paracelsus-Elena-Klinik, Kassel, Germany.

Science (New York, N.Y.)
|August 18, 2022
PubMed
Summary

A specific glycoprotein may serve as an early indicator for Parkinson's disease progression. This finding could lead to better monitoring of the neurodegenerative condition.

Area of Science:

  • Neurobiology
  • Biomarker Discovery

Background:

  • Parkinson's disease is a progressive neurodegenerative disorder.
  • Identifying reliable biomarkers for disease progression is crucial for effective management.

Purpose of the Study:

  • To investigate the potential of a specific glycoprotein as a biomarker for Parkinson's disease pathogenic progression.

Main Methods:

  • Analysis of glycoprotein levels in relevant biological samples.
  • Correlation of glycoprotein levels with disease severity and progression markers.

Main Results:

  • A particular glycoprotein was identified as a potential indicator of Parkinson's disease progression.

Conclusions:

More Related Videos

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
04:08

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease

Published on: January 18, 2021

2.9K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

18.1K

Related Experiment Videos

Last Updated: Sep 1, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.0K
Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
04:08

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease

Published on: January 18, 2021

2.9K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

18.1K
  • This glycoprotein shows promise as a biomarker for monitoring Parkinson's disease.
  • Further research is warranted to validate its clinical utility.